Genprex Inc (GNPX)

$3.35 0.00 (N/A)
Market Cap 2.75M
Revenue (ttm) 0.00
Net Income (ttm) -16.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 28,100
Avg Vol 214,127
Day's Range N/A - N/A
Shares Out 820,000.00
Stochastic %K 8%
Beta -0.94
Analysts Strong Buy
Price Target $164.84

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 774 4679
Address:
3300 Bee Cave Road, Suite 650-227, Austin, United States
POSGNPX
POSGNPX Sep. 13 at 3:42 AM
$GNPX yea give these coc sukas another 2 years of your money to blow on ho’s
0 · Reply
TwongStocks
TwongStocks Sep. 11 at 8:53 PM
$GNPX ACCLAIM-3 trial register was updated https://clinicaltrials.gov/study/NCT05703971 Summary of changes: • Primary completion date changed from 2026-06 to 2027-12 • Study completion changed from 2027-08 to 2028-06
1 · Reply
POSGNPX
POSGNPX Sep. 10 at 9:40 PM
$GNPX dump, dump, dump it
0 · Reply
buhbye
buhbye Sep. 10 at 3:28 PM
$GNPX under $1.00 soon
0 · Reply
Jpeel1972
Jpeel1972 Sep. 10 at 1:50 PM
$GNPX as bad as it sounds, the price should really start dropping more drastically. They have a history of diluting big tine into presentation pr’s.
2 · Reply
bmontgo
bmontgo Sep. 4 at 9:52 PM
$GNPX Hi, any fellow bag holders out there 🥲
4 · Reply
ka1954
ka1954 Sep. 4 at 3:21 PM
$GNPX GNPX is 10x better company than BIAF but stock is 10x worse
1 · Reply
OverTheCounter
OverTheCounter Sep. 4 at 12:28 AM
$GNPX This is red on big green day.
0 · Reply
POSGNPX
POSGNPX Sep. 3 at 4:14 PM
$GNPX come on now people show us your complete stupidity and ignorance. Spend a couple of hundred bucks and buy this stock.. four or five shares and you’ll be rich rich rich. Hurry, hurry before it’s listed and bankrupt.. buy it buy it buy it so I can sell sell sell 
0 · Reply
buhbye
buhbye Sep. 3 at 3:14 PM
$GNPX it’s a shame this is even still listed, blatant scams shouldn’t be allowed
0 · Reply
Latest News on GNPX
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 8, 2026, 8:00 AM EDT - 4 days ago

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Genprex selects manufacturing organization for diabetes gene therapy

2026-08-18T11:10:18.000Z - 25 days ago

Genprex selects manufacturing organization for diabetes gene therapy

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Aug 18, 2026, 7:00 AM EDT - 25 days ago

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Genprex announces collaboration with Roche Diagnostics

2026-08-03T11:11:17.000Z - 5 weeks ago

Genprex announces collaboration with Roche Diagnostics

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Aug 3, 2026, 7:00 AM EDT - 5 weeks ago

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Genprex trading halted, news pending

2026-07-15T23:50:11.000Z - 1 month ago

Genprex trading halted, news pending

Genprex says CIPO issues Notice of Allowance for patent

2026-06-22T13:09:12.000Z - 2 months ago

Genprex says CIPO issues Notice of Allowance for patent

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

Jun 22, 2026, 9:00 AM EDT - 2 months ago

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

Genprex to Participate at BIO International Convention 2026

Jun 17, 2026, 9:00 AM EDT - 2 months ago

Genprex to Participate at BIO International Convention 2026

Genprex files $250M mixed securities shelf

2026-06-05T21:05:10.000Z - 3 months ago

Genprex files $250M mixed securities shelf

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

May 26, 2026, 8:00 AM EDT - 3 months ago

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Genprex collaborators present positive preclinical data of GPX-002 in diabetes

2026-05-14T16:54:55.000Z - 4 months ago

Genprex collaborators present positive preclinical data of GPX-002 in diabetes

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

May 14, 2026, 8:00 AM EDT - 4 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Genprex receives patent grant from The Israel Patent Office

2026-04-30T17:03:52.000Z - 4 months ago

Genprex receives patent grant from The Israel Patent Office

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

Genprex enters research agreement with UT MD Anderson

2026-04-21T11:09:56.000Z - 4 months ago

Genprex enters research agreement with UT MD Anderson

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

Apr 21, 2026, 7:00 AM EDT - 4 months ago

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR

2026-04-20T11:26:41.000Z - 4 months ago

Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Apr 20, 2026, 7:00 AM EDT - 4 months ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex collaborators present on use of Reqorsa at AACR meeting

2026-03-18T11:11:22.000Z - 5 months ago

Genprex collaborators present on use of Reqorsa at AACR meeting

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex to Participate at BIO Europe Spring 2026

Mar 10, 2026, 7:00 AM EDT - 6 months ago

Genprex to Participate at BIO Europe Spring 2026

Genprex granted Japanese and EU patents for Reqorsa Gene Therapy

2026-02-23T13:12:47.000Z - 6 months ago

Genprex granted Japanese and EU patents for Reqorsa Gene Therapy

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Feb 23, 2026, 8:00 AM EST - 6 months ago

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Genprex’s patent application for Reqorsa Gene Therapy accepted by IP Australia

2026-02-10T13:05:58.000Z - 7 months ago

Genprex’s patent application for Reqorsa Gene Therapy accepted by IP Australia

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Feb 10, 2026, 8:00 AM EST - 7 months ago

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Jan 7, 2026, 7:00 AM EST - 8 months ago

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Genprex reports ‘positive’ preclinical data from study of GPX-002

2026-01-06T12:05:20.000Z - 8 months ago

Genprex reports ‘positive’ preclinical data from study of GPX-002

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Jan 6, 2026, 7:00 AM EST - 8 months ago

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Genprex publishes data from Acclaim-1 Phase 1 trial of Reqorsa Gene Therapy

2025-11-24T12:10:18.000Z - 9 months ago

Genprex publishes data from Acclaim-1 Phase 1 trial of Reqorsa Gene Therapy

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Nov 24, 2025, 7:00 AM EST - 9 months ago

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Genprex files to sell 1.28M shares of common stock for holders

2025-11-21T22:00:33.000Z - 9 months ago

Genprex files to sell 1.28M shares of common stock for holders

Genprex adds Gabrail Cancer Center for Acclaim clinical trials 1 and 3

2025-11-19T12:10:46.000Z - 9 months ago

Genprex adds Gabrail Cancer Center for Acclaim clinical trials 1 and 3

AZN

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Nov 19, 2025, 7:00 AM EST - 9 months ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex granted U.S. patenet for Reqorsa Gene Therapy in cancer

2025-11-18T12:21:46.000Z - 9 months ago

Genprex granted U.S. patenet for Reqorsa Gene Therapy in cancer

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Nov 18, 2025, 7:00 AM EST - 9 months ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex on path to receive European patent for Reqorsa in cancer

2025-11-04T12:50:41.000Z - 10 months ago

Genprex on path to receive European patent for Reqorsa in cancer

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Nov 4, 2025, 7:00 AM EST - 10 months ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex trading resumes

2025-10-28T15:30:20.000Z - 10 months ago

Genprex trading resumes

Genprex trading halted, volatility trading pause

2025-10-28T15:25:18.000Z - 10 months ago

Genprex trading halted, volatility trading pause

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 11:19 AM EDT - 10 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 28, 2025, 7:00 AM EDT - 10 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 8:12 AM EDT - 10 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 7:00 AM EDT - 10 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Sep 2, 2025, 8:30 AM EDT - 1 year ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 18, 2025, 9:29 AM EDT - 1 year ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 24, 2025, 9:25 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 1 year ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO 2025 International Convention

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Genprex to Participate at BIO 2025 International Convention

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 29, 2025, 7:00 AM EDT - 1 year ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 28, 2025, 7:00 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 7, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

May 6, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Apr 22, 2025, 8:15 AM EDT - 1 year ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 25, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO Europe Spring 2025

Mar 4, 2025, 8:15 AM EST - 1 year ago

Genprex to Participate at BIO Europe Spring 2025

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 19, 2025, 8:15 AM EST - 1 year ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 18, 2025, 8:15 AM EST - 1 year ago

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Feb 13, 2025, 8:15 AM EST - 1 year ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

POSGNPX
POSGNPX Sep. 13 at 3:42 AM
$GNPX yea give these coc sukas another 2 years of your money to blow on ho’s
0 · Reply
TwongStocks
TwongStocks Sep. 11 at 8:53 PM
$GNPX ACCLAIM-3 trial register was updated https://clinicaltrials.gov/study/NCT05703971 Summary of changes: • Primary completion date changed from 2026-06 to 2027-12 • Study completion changed from 2027-08 to 2028-06
1 · Reply
POSGNPX
POSGNPX Sep. 10 at 9:40 PM
$GNPX dump, dump, dump it
0 · Reply
buhbye
buhbye Sep. 10 at 3:28 PM
$GNPX under $1.00 soon
0 · Reply
Jpeel1972
Jpeel1972 Sep. 10 at 1:50 PM
$GNPX as bad as it sounds, the price should really start dropping more drastically. They have a history of diluting big tine into presentation pr’s.
2 · Reply
bmontgo
bmontgo Sep. 4 at 9:52 PM
$GNPX Hi, any fellow bag holders out there 🥲
4 · Reply
ka1954
ka1954 Sep. 4 at 3:21 PM
$GNPX GNPX is 10x better company than BIAF but stock is 10x worse
1 · Reply
OverTheCounter
OverTheCounter Sep. 4 at 12:28 AM
$GNPX This is red on big green day.
0 · Reply
POSGNPX
POSGNPX Sep. 3 at 4:14 PM
$GNPX come on now people show us your complete stupidity and ignorance. Spend a couple of hundred bucks and buy this stock.. four or five shares and you’ll be rich rich rich. Hurry, hurry before it’s listed and bankrupt.. buy it buy it buy it so I can sell sell sell 
0 · Reply
buhbye
buhbye Sep. 3 at 3:14 PM
$GNPX it’s a shame this is even still listed, blatant scams shouldn’t be allowed
0 · Reply
ka1954
ka1954 Sep. 3 at 3:08 PM
$GNPX no activity in the stock means, people get frustrated and just sell their shares bringing to all time lows every few days
0 · Reply
RandDMomentum
RandDMomentum Sep. 3 at 2:58 PM
$GNPX ​Nothing will happen. Don't buy... let them choke on their ATM. You won't see your money back anyway, not much difference between -90% and -100%. They've raised over $130M just to burn $18M+ a year with zero horizon. They have enough cash left for less than a year (15M), and no future( 2.8 MC). Delist this garbage already so they’re forced to blow a whole new bubble and actually work for once. :)
1 · Reply
Jpeel1972
Jpeel1972 Sep. 3 at 3:18 AM
$GNPX did something happen overnight
0 · Reply
buhbye
buhbye Sep. 1 at 4:26 PM
$GNPX please tell me there aren’t people out there actually holding this worthless junk
1 · Reply
ka1954
ka1954 Sep. 1 at 2:26 PM
$GNPX another problem is we have idiots here who dont hold anything and sell at a drop of a hat
1 · Reply
ka1954
ka1954 Sep. 1 at 1:50 PM
$GNPX right on schedule. every few days a new all time low
1 · Reply
Jpeel1972
Jpeel1972 Aug. 31 at 2:53 PM
$GNPX the big drop should happen fairly quickly
0 · Reply
Tunacanman69
Tunacanman69 Aug. 28 at 2:43 PM
$GNPX coffner won’t let this run he’s to greedy in his ways. His ways work. Why change them?
1 · Reply
RandDMomentum
RandDMomentum Aug. 28 at 10:17 AM
$GNPX ⚠️ WARNING / REALITY CHECK: Learn from your mistakes and scale out 5–15% weekly. Even a 200% pump barely recovers last month's split price because relentless dilution kills every move. PRs have zero substance to justify a run. They raised over $100M, yet market cap sits at ~$3M—while management pays themselves more in raises and bonuses than the whole company is worth, with zero insider buying. The chart might look like a bounce setup, but the dilution overrides any technicals. Stop filling their ATM—let them bleed out and get delisted faster. Anyone holding is just losing.
1 · Reply
ka1954
ka1954 Aug. 27 at 8:11 PM
$GNPX why this after hours fuckery? is this a joke, when we all know this will be killed tomorrow and brought back down another -10% or so
0 · Reply